Overall, IOL surgery climbed 2.5 percent in Q3-2011 with premium procedures again posting double-digit growth.
In 2011’s third quarter, total retinal procedure volume rose by more than 11 percent year over year, as IVT injections surged.
The global market in dry eye products will see steady, if modest, growth through 2016, much of which will be driven by aging, increased affluence, and access to health care in the developing world.
Regeneron/Bayer released integrated two-year results for Eylea in wet AMD in the VIEW studies. VA gains were mostly maintained, but a PRN protocol proved less effective than more regular dosing.
This month's news includes the latest from Avedro, Bausch & Lomb, Laboratoria Pfortner Cornealent SACIF, Waicon, Regeneron, Bayer HealthCare, Alcon and NovaBay Pharmaceuticals.
After three quarters with procedures inching higher, refractive surgery dips slightly.
You are not currently logged in.
©2018 Market Scope
Lost your Password